Response to Neoadjuvant Chemotherapy in Triple Negative Breast tumors.
收藏官方服务：
资源简介：
Response to Neoadjuvant Chemotherapy in Triple Negative Breast tumors.
应用场景：
创建时间：
2016-03-24
相关数据集
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
We report the ability of a gene expression signature to predict response to neoadjuvant chemotherapy in early breast cancer, and also describe transcriptomic changes during treatment Overall design: T
NIAID Data Ecosystem60
On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer
Background: Neoadjuvant chemotherapy is increasingly being used to preoperatively shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes ass
NIAID Data Ecosystem50
Biomarker analysis of neoadjuvant Doxorubicin/Cyclophosphamide followed by Ixabepilone or Paclitaxel in early-stage breast cancer
A randomized, open-label, multicenter, phase II trial (NCT00455533) enrolled previously untreated women with histologically-confirmed primary invasive breast adenocarcinoma (T2–3, N0–3, M0, tumor size
NIAID Data Ecosystem30
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab on NSABP B-40. Homo sapiens
"Source of Patients Patients entered into this study were from the NSABP B-40 trial in which patients were randomized to one of three chemotherapy regimens with one-half of the patients also randomize
NIAID Data Ecosystem50
Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
IntroductionSPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast ca
Figshare2016-01-18 更新40
